Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of sulforaphane or nanoparticles thereof to preparation of medicine for improving embryonic nervous system dysplasia caused by heterocyclic amine intake of pregnant women

A technology of nervous system development and sulforaphane, applied in the field of medicine, can solve problems such as fetal toxicity, achieve the effect of expanding the application range, improving the application value, and improving the development of the embryonic nervous system.

Active Publication Date: 2020-10-13
JINAN UNIVERSITY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, even drugs that have no serious adverse effects on the mother may be toxic to the fetus during pregnancy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sulforaphane or nanoparticles thereof to preparation of medicine for improving embryonic nervous system dysplasia caused by heterocyclic amine intake of pregnant women
  • Application of sulforaphane or nanoparticles thereof to preparation of medicine for improving embryonic nervous system dysplasia caused by heterocyclic amine intake of pregnant women
  • Application of sulforaphane or nanoparticles thereof to preparation of medicine for improving embryonic nervous system dysplasia caused by heterocyclic amine intake of pregnant women

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Preparation and self-assembly of embodiment 1 nanometer sulforaphane

[0065] refer to figure 1 As shown in the process, the drug sulforaphane is encapsulated into mPEG5K-PGA10K through self-assembly. The specific operation is as follows:

[0066] 1) Dissolving sulforaphane in pure dimethylsulfoxide (DMSO) to obtain a SFN-DMSO solution with a concentration of 56.4mmol / L;

[0067] 2) dissolving mPEG5K-PGA10K in sodium lactate Ringer solution (Sodium lactate ringer solution: LR, a kind of isotonic intravenous injection, available on the market, purchased from Shanghai Zhuocai Biotechnology Co., Ltd., article number ZC-A0302), Obtain an mPEG5K-PGA10K solution with a concentration of 0.05 μg / μL;

[0068] 3) After 10 minutes, gently drop 10 μL of mPEG5K-PGA10K solution into 100 μL of SFN-DMSO solution and oscillate fully to obtain a mixed solution; ensure that a supersaturated sulforaphane solution can be obtained;

[0069] 4) The mixture was sonicated for 30 minutes to ...

Embodiment 2

[0074] The drug loading efficiency analysis of embodiment 2 nanometer sulforaphane

[0075] The drug-loaded nanoparticles were separated by low-speed centrifugation, the content of free drug in the supernatant was determined by high-performance liquid chromatography, and the peak area was determined. Take the standard sample solution (DMSO, DMSO+SFN), the supernatant (Nanoparticles + , Nanoparticles - ) into high performance liquid chromatography (column: Agilent C18 (250mm×4.6mm, 5μm); mobile phase: methanol-water (10:90); flow rate: 1.0mL min -1 ; Detection wavelength: 266nm; Column temperature: 30°C; Injection volume: 10 μL. ), record the chromatogram, the chromatogram see figure 2 . Under this chromatographic condition, sulforaphane (Sulforaphane) achieves baseline separation and a good peak shape with a retention time of 7.8min, and solvents and auxiliary materials do not interfere with the determination of sulforaphane ( figure 2 A). The amount of free drug was c...

Embodiment 3

[0076] The nano-characteristic detection of embodiment 3 nanometer sulforaphane

[0077] The nano-characteristics of the prepared nano-sulforaphane were measured by a Zeta potential analyzer, and the results were as follows image 3 shown. At pH7.4, the Zeta potential (ZP) of nano-sulforaphane is -7.21mV±1.3mV, and the polydispersity index (PDI) is 0.430+ / -0.095( image 3 A). The diluted nanoparticles were analyzed by a laser particle size distribution measuring instrument for particle size distribution ( image 3 B), the morphology and size of the nanoparticles were analyzed by transmission electron microscopy ( image 3 C). According to the transmission electron microscope (TEM) pictures of nano-sulforaphane, it can be observed that nano-sulforaphane is a uniform spherical particle with a particle size of 195nm±32nm, and the particle size distribution is relatively uniform.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of sulforaphane or nanoparticles thereof to preparation of a medicine for improving embryonic nervous system dysplasia caused by heterocyclic amine intake of pregnant women. The invention provides a new application of the sulforaphane, namely an embryonic development protection application, so that the application range of the sulforaphane is expanded, the application value of the sulforaphane is improved, a new nano-drug for improving the embryonic nervous system dysplasia induced by the heterocyclic amine intake of the pregnant women is further developed, and the sulforaphane has a good application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and particularly relates to the application of sulforaphane or its nanoparticles in the preparation of medicines for improving dysplasia of the embryonic nervous system caused by the intake of heterocyclic amines in pregnant women. Background technique [0002] The neural tube develops into the body's central nervous system. The retrograde movement of Heinz's ganglion induces the formation of notochord and neural plate. After being induced to differentiate, the neural plate bends and folds dorsally and fuses to form the neural tube. The deformity caused by the abnormal development of the neural tube, called neural tube defect, is a serious deformity disease, including anencephaly, encephalocele, exocephalus, craniospina bifida, etc. Neural tube defects (NTDs) are the most common birth defects, accounting for about 0.5‰-2‰ of births worldwide (Sanna et al., Nat Genet 2019). With the closure of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/26A61K9/127A61K9/107A61K47/34B82Y5/00B82Y40/00A61P25/00
CPCA61K31/26A61K9/1272A61K9/1075A61K47/34A61P25/00B82Y5/00B82Y40/00
Inventor 王广杨雪松张萍穆斯塔法·辛迪刘畅程欣
Owner JINAN UNIVERSITY
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com